about
Systematic adjudication of myocardial infarction end-points in an international clinical trialDisagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT studyDynamic 3D echocardiography in virtual reality.Prehospital thrombolysis with reteplase: the Nijmegen/Rotterdam studyEvaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromesActivation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudyTroponin T levels in patients with acute coronary syndromes, with or without renal dysfunctionLong-term effect of perindopril on coronary atherosclerosis progression (from the perindopril's prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study)Quality of hospital and outpatient care after stroke or transient ischemic attack: insights from a stroke survey in the NetherlandsDabigatran versus warfarin in patients with mechanical heart valvesThe Cardiology Audit and Registration Data Standards (CARDS), European data standards for clinical cardiology practice.Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes.Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromes.The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.Intra-operative assessment of human pulmonary alveoli in vivo using Sidestream Dark Field imaging: a feasibility study.Risk stratification for sudden cardiac death: current status and challenges for the futureConventional hemodynamic resuscitation may fail to optimize tissue perfusion: an observational study on the effects of dobutamine, enoximone, and norepinephrine in patients with acute myocardial infarction complicated by cardiogenic shockGuidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology.Universal definition of myocardial infarction.Changes in clinical profile, treatment, and mortality in patients hospitalised for acute myocardial infarction between 1985 and 2008Third universal definition of myocardial infarction.A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study.[Guidelines on the management of stable angina pectoris. Executive summary].Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach.The need for resources for clinical research: proceedings of a policy conference held at the European Heart House, 27-28 June 2002: executive summary.Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis.Should all patients with an acute myocardial infarction be referred for direct PTCA?Prehospital versus hospital fibrinolytic therapy using automated versus cardiologist electrocardiographic diagnosis of myocardial infarction: abortion of myocardial infarction and unjustified fibrinolytic therapy.The additional value of patient-reported health status in predicting 1-year mortality after invasive coronary procedures: a report from the Euro Heart Survey on Coronary Revascularisation.Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups.Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure.Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials.Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies.Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial.Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk ModelPharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy.Euro Heart Survey 2009 Snapshot: regional variations in presentation and management of patients with AMI in 47 countries.Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.Management of cardiogenic shock: focus on tissue perfusion.
P50
Q24805625-6B8EA047-6E2C-44F9-895B-F8D2A9559B88Q24805692-5B84B7FC-9539-476F-A6FD-18D10F3DB7CCQ25257094-9DC2FFF2-9A7A-40F1-9666-3D2210952A51Q28165180-31A84504-B442-4109-9453-BA45043692D3Q28166580-AE6E92A0-07DC-4D9B-9A6C-3836C46C54BAQ28167111-D4BBFF7B-C820-465F-8EA4-78214B1F9E88Q28193293-B9119741-A074-4361-9DFD-CEB5168B5CF5Q28218425-9C61D68B-2C8D-4F16-ABC0-1AB6E018E2A6Q28218464-0A8FA508-DBB2-4A2E-B5A5-2BB6D7C5E7E1Q28297637-38EC7A0E-A582-45C4-8766-66F93325DE48Q30979240-5521A9DB-6916-40F2-9CB9-0A6AD478E10DQ33265015-3E8A49F7-F2E4-4B77-A3A4-2363B402BF5FQ33347590-0ED42A06-CD8E-4F30-8C98-76F8B2B8B21DQ33365736-F0895B5C-5DB7-48B8-B3CE-93B4AE4191FBQ33426787-37BEF7A1-A11E-4399-BE29-0DAC29735602Q33507501-EC548BEE-6664-45F2-B9A5-15FF43C487C6Q33827123-97FEDB84-977D-45FE-8ABA-D84A75C4E170Q33989560-72BD491C-19E4-495D-9448-E9B9E75D3D61Q33996248-D14F1D52-B13D-45BA-A8FB-77ED3AD51909Q34007701-4889A6D9-BF50-444F-BA31-D34FC3C195BAQ34071675-6E6A1F02-495D-4DC1-B31C-3A55B7B1F142Q34295914-BA5D8FFD-94E8-4258-BF75-600430B8367CQ34326602-90296A82-8AB2-4195-B8F3-7FC32B929A56Q34573219-4BCD9766-6158-4663-B3AF-8D68BE0B9B31Q35079924-3C1A7F33-391F-4D03-9B7C-CCA55F98BA9BQ35153784-1EC772CC-70DA-49B5-A246-5892B148C508Q35419293-C011FFDE-F855-4681-802F-A47E97189AA5Q35583073-9482341E-0AFF-4648-BD64-666F523B1F4FQ35681722-D17756DA-88B8-4DBB-A46D-719129C2CD4CQ35773247-D4B22187-B949-407B-98EB-E65B4E3B52AAQ35773362-605D27B7-DD57-4DEC-A4E3-B7AA55815608Q36267709-EE7BF266-41D9-40CE-AAEA-0797C9A16AA9Q36590986-605A6C34-B0FC-4BF4-BEC6-034C8CD61209Q36738253-C2938A88-E414-402A-B995-4F048AFD6CC0Q37012910-BFB3E599-5E3B-4BAB-B1C3-75C11C7FE58AQ37090714-2B0CE0A6-F1E4-423D-BB4A-0B177C9B879BQ37180481-6180CD39-D5E1-4D15-9C42-4E7189E90D78Q37291921-CD2A2524-3DF8-48DB-9BB7-81F477C1140CQ37451495-BF13ECBA-5D18-4241-BA0B-38D6EB4FBFCEQ37547340-3B9BB783-6AE7-42E4-AFC1-AB9DF5277415
P50
name
Maarten L Simoons
@ast
Maarten L Simoons
@en
Maarten L Simoons
@nl
type
label
Maarten L Simoons
@ast
Maarten L Simoons
@en
Maarten L Simoons
@nl
prefLabel
Maarten L Simoons
@ast
Maarten L Simoons
@en
Maarten L Simoons
@nl